LOGIN  |  REGISTER
Assertio

RadNet to Present at the BofA Securities 2023 Leveraged Finance Conference on November 28, 2023

November 27, 2023 | Last Trade: US$62.41 0.78 -1.23

LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the BofA Securities 2023 Leveraged Finance Conference in Boca Raton, FL on Tuesday, November 28, 2023 at 11:10 a.m. Pacific Time (2:10 p.m. Eastern Time).

There will be simultaneous and archived webcasts available here and www.radnet.com under the “About RadNet'' menu section and “News and Press Releases'' sub-menu of the website.

Details for RadNet's Presentation:
Date:   Tuesday, November 28, 2023
Time: 11:10 a.m. Pacific Time (2:10 p.m. Eastern Time)
Location: Boca Raton Resort, Boca Raton, FL

About RadNet, Inc.

RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 366 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, inclusive of full-time and per diem employees and technologists, RadNet has a total of over 9,000 employees. For more information, visit http://www.radnet.com

CONTACT:

RadNet, Inc.

Mark Stolper, 310-445-2800

Executive Vice President and Chief Financial Officer

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Surmodics

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB